When directly comparing cross-presenting capacities of DCs and primary macrophages isolated from human peritoneal tumor ascites in vitro, it was found that HLA-DR+CD11c+CD1c−CD16+ tumor macrophages are even more effective than HLA-DR+CD11c+CD1c+CD16− DCs at cross-presentation to the LT12 CD8+ T-cell lines (IFN-γ) recognizing the tumor-specific antigen MelanA, which does not require costimulation for activation (45). The gene discussed is ITGAX; the disease is neoplasm.